Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
Department of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, USA.
Xenotransplantation. 2018 May;25(3):e12420. doi: 10.1111/xen.12420.
To date, the only successful means of achieving allogeneic transplantation tolerance in the clinic has involved induction of mixed lymphohematopoietic chimerism. Such chimerism was first achieved in mice and subsequently in large animals, including miniature swine, monkeys and most recently humans. The mechanism of tolerance has differed between models, involving both deletional and regulatory mechanisms, in varying proportions, depending on the model. Considerable progress has also been made toward induction of tolerance across the xenogeneic pig-to-primate barrier, although complete success has not yet been achieved. The two approaches toward xenograft tolerance currently being investigated both involve establishment of a mixture of host and donor cells in the thymus, in one case through administration of donor bone marrow to the recipient and in the other through vascularized donor thymus transplantation to a thymectomized recipient. Hopefully, a combination of these approaches may provide an effective means for achieving full tolerance and thereby bringing xenograft organ transplantation to the clinic.
迄今为止,临床上实现同种异体移植耐受的唯一成功方法涉及诱导混合淋巴造血嵌合。这种嵌合首先在小鼠中实现,随后在大型动物中实现,包括小型猪、猴子,最近在人类中也实现了。耐受的机制在不同模型之间有所不同,涉及删除和调节机制,其比例因模型而异。在跨越异种猪-灵长类动物障碍诱导耐受方面也取得了相当大的进展,尽管尚未完全成功。目前正在研究的两种异种移植物耐受方法都涉及在胸腺中建立宿主和供体细胞的混合物,一种方法是通过给受体输注供体骨髓,另一种方法是通过血管化供体胸腺移植到胸腺切除的受体中。希望这些方法的组合可能为实现完全耐受提供有效手段,从而将异种器官移植引入临床。